Headlines about Insulet (NASDAQ:PODD) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Insulet earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 45.110981429909 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of research firms have commented on PODD. Jefferies Group restated a “buy” rating and issued a $90.00 price target on shares of Insulet in a report on Friday, February 23rd. Cowen restated an “outperform” rating and issued a $90.00 price target (up from $80.00) on shares of Insulet in a report on Thursday, February 22nd. Stephens restated an “equal weight” rating and issued a $81.00 price target (up from $60.00) on shares of Insulet in a report on Thursday, February 22nd. BidaskClub upgraded shares of Insulet from a “hold” rating to a “buy” rating in a report on Friday, March 9th. Finally, BMO Capital Markets began coverage on shares of Insulet in a report on Monday, March 5th. They issued an “outperform” rating and a $90.00 price target for the company. Seven analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $75.00.
Shares of NASDAQ PODD opened at $87.82 on Wednesday. The stock has a market cap of $4,984.67, a PE ratio of -190.91 and a beta of 1.37. Insulet has a 1 year low of $38.43 and a 1 year high of $88.88. The company has a quick ratio of 5.85, a current ratio of 6.24 and a debt-to-equity ratio of 3.57.
Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The business had revenue of $130.50 million for the quarter, compared to analyst estimates of $125.16 million. Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The firm’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.16) earnings per share. research analysts anticipate that Insulet will post -0.29 EPS for the current fiscal year.
In other news, Director John A. Fallon sold 9,000 shares of Insulet stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $84.10, for a total transaction of $756,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Shacey Petrovic sold 1,319 shares of Insulet stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $101,312.39. The disclosure for this sale can be found here. Insiders have sold 28,800 shares of company stock valued at $2,412,739 over the last quarter. Corporate insiders own 3.60% of the company’s stock.
WARNING: “Insulet (PODD) Receives News Impact Score of 0.24” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/18/insulet-podd-receives-news-impact-score-of-0-24.html.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.